NO135892B - - Google Patents
Download PDFInfo
- Publication number
- NO135892B NO135892B NO4558/71A NO455871A NO135892B NO 135892 B NO135892 B NO 135892B NO 4558/71 A NO4558/71 A NO 4558/71A NO 455871 A NO455871 A NO 455871A NO 135892 B NO135892 B NO 135892B
- Authority
- NO
- Norway
- Prior art keywords
- saxitoxin
- lidocaine
- bupivacaine
- injection
- concentration
- Prior art date
Links
- RPQXVSUAYFXFJA-HGRQIUPRSA-N saxitoxin Chemical compound NC(=O)OC[C@@H]1N=C(N)N2CCC(O)(O)[C@@]22N=C(N)N[C@@H]12 RPQXVSUAYFXFJA-HGRQIUPRSA-N 0.000 claims description 29
- RPQXVSUAYFXFJA-UHFFFAOYSA-N saxitoxin hydrate Natural products NC(=O)OCC1N=C(N)N2CCC(O)(O)C22NC(N)=NC12 RPQXVSUAYFXFJA-UHFFFAOYSA-N 0.000 claims description 29
- 229960004194 lidocaine Drugs 0.000 claims description 27
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 claims description 26
- 239000000243 solution Substances 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 claims description 15
- 229960003150 bupivacaine Drugs 0.000 claims description 15
- 239000003589 local anesthetic agent Substances 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000005526 vasoconstrictor agent Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 description 11
- 230000003444 anaesthetic effect Effects 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 7
- 239000003053 toxin Substances 0.000 description 6
- 231100000765 toxin Toxicity 0.000 description 6
- 108700012359 toxins Proteins 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- 210000002414 leg Anatomy 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 4
- 229930182837 (R)-adrenaline Natural products 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 229960005139 epinephrine Drugs 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000007659 motor function Effects 0.000 description 3
- 230000036407 pain Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010039757 Scrotal pain Diseases 0.000 description 2
- 230000007059 acute toxicity Effects 0.000 description 2
- 231100000403 acute toxicity Toxicity 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 229960005015 local anesthetics Drugs 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- CDJDGQRYHDBSKC-UHFFFAOYSA-N 2,3,4,5,6,7,8,9-octahydro-1h-purine Chemical group C1NCNC2NCNC21 CDJDGQRYHDBSKC-UHFFFAOYSA-N 0.000 description 1
- -1 2-imino-8-amino-6-methyl-3-β-carboxyethylpurine Chemical compound 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000238366 Cephalopoda Species 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000237536 Mytilus edulis Species 0.000 description 1
- 241001238245 Saxidomus Species 0.000 description 1
- 208000004891 Shellfish Poisoning Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241001122767 Theaceae Species 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000001432 effect on motor function Effects 0.000 description 1
- 238000002692 epidural anesthesia Methods 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- ZRALSGWEFCBTJO-UHFFFAOYSA-N guanidine group Chemical group NC(=N)N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 241000238565 lobster Species 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 235000020638 mussel Nutrition 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 238000009519 pharmacological trial Methods 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000026416 response to pain Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 210000003497 sciatic nerve Anatomy 0.000 description 1
- 210000004706 scrotum Anatomy 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 239000000238 shellfish toxin Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000000273 spinal nerve root Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 210000003813 thumb Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10994271A | 1971-01-26 | 1971-01-26 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO135892B true NO135892B (enExample) | 1977-03-14 |
| NO135892C NO135892C (no) | 1978-05-16 |
Family
ID=22330411
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO4557/71A NO135891C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
| NO4558/71A NO135892C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO4557/71A NO135891C (no) | 1971-01-26 | 1971-12-10 | Fremgangsmaate til fremstilling av en lokalanestetisk virksom injeksjonsopploesning |
Country Status (18)
| Country | Link |
|---|---|
| AT (2) | AT310938B (enExample) |
| AU (1) | AU465875B2 (enExample) |
| BE (2) | BE776769A (enExample) |
| BR (2) | BR7108429D0 (enExample) |
| CA (2) | CA986012A (enExample) |
| DD (2) | DD96144A5 (enExample) |
| DE (2) | DE2163054C3 (enExample) |
| DK (2) | DK130389B (enExample) |
| ES (2) | ES398108A1 (enExample) |
| FR (2) | FR2123277B1 (enExample) |
| GB (1) | GB1370904A (enExample) |
| HU (2) | HU162185B (enExample) |
| IE (2) | IE35937B1 (enExample) |
| LU (1) | LU64664A1 (enExample) |
| NL (2) | NL7117401A (enExample) |
| NO (2) | NO135891C (enExample) |
| SE (2) | SE391286B (enExample) |
| ZA (2) | ZA718326B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4917894A (en) * | 1988-06-29 | 1990-04-17 | Beecham Inc. | Rapid-onset long-duration oral anesthetic composition |
| US6030974A (en) * | 1997-04-02 | 2000-02-29 | The Regents Of The University Of California | Method of anesthesia |
| WO1998051290A2 (en) * | 1997-05-16 | 1998-11-19 | Children's Medical Center Corporation | Local anesthetic formulations comprising a site 1 sodium channel blocker combined with a second active agent |
| RU2277097C1 (ru) * | 2004-12-27 | 2006-05-27 | Институт Молекулярной Генетики Российской Академии Наук (Имг Ран) | Высокомеченный тритием дигидрохлорид [3h]сакситоксина |
| CN101563079B (zh) | 2006-03-27 | 2012-12-05 | 威克斯药业有限公司 | 钠通道阻滞剂在制备治疗由于化疗而产生的神经病理性疼痛的药物中的用途 |
| US8952152B2 (en) | 2009-03-24 | 2015-02-10 | Proteus S.A. | Methods for purifying phycotoxins, pharmaceutical compositions containing purified phycotoxins, and methods of use thereof |
| KR20210062693A (ko) | 2013-03-15 | 2021-05-31 | 더 칠드런스 메디칼 센터 코포레이션 | 지속성 국소 마취용 네오삭시톡신 조합 제형 |
-
1971
- 1971-12-07 SE SE7115654A patent/SE391286B/xx unknown
- 1971-12-07 SE SE7115655A patent/SE391127B/xx unknown
- 1971-12-10 NO NO4557/71A patent/NO135891C/no unknown
- 1971-12-10 NO NO4558/71A patent/NO135892C/no unknown
- 1971-12-13 ZA ZA718326A patent/ZA718326B/xx unknown
- 1971-12-13 ZA ZA718327A patent/ZA718327B/xx unknown
- 1971-12-14 DK DK609571AA patent/DK130389B/da unknown
- 1971-12-16 HU HU71AA689A patent/HU162185B/hu unknown
- 1971-12-16 BE BE776769A patent/BE776769A/xx unknown
- 1971-12-16 BE BE776768A patent/BE776768A/xx unknown
- 1971-12-16 HU HUAA688A patent/HU162347B/hu unknown
- 1971-12-17 AT AT1084871A patent/AT310938B/de not_active IP Right Cessation
- 1971-12-17 DD DD159910A patent/DD96144A5/xx unknown
- 1971-12-17 DD DD159688A patent/DD96400A5/xx unknown
- 1971-12-17 FR FR7145542A patent/FR2123277B1/fr not_active Expired
- 1971-12-17 NL NL7117401A patent/NL7117401A/xx unknown
- 1971-12-17 NL NL7117404A patent/NL7117404A/xx not_active Application Discontinuation
- 1971-12-17 DK DK619971A patent/DK131606C/da active
- 1971-12-17 FR FR7145543A patent/FR2123278B1/fr not_active Expired
- 1971-12-17 CA CA130,378A patent/CA986012A/en not_active Expired
- 1971-12-17 AT AT1084971A patent/AT310939B/de not_active IP Right Cessation
- 1971-12-17 CA CA130,377A patent/CA983850A/en not_active Expired
- 1971-12-17 GB GB5865871A patent/GB1370904A/en not_active Expired
- 1971-12-18 DE DE2163054A patent/DE2163054C3/de not_active Expired
- 1971-12-18 ES ES398108A patent/ES398108A1/es not_active Expired
- 1971-12-18 ES ES398109A patent/ES398109A1/es not_active Expired
- 1971-12-18 DE DE19712163055 patent/DE2163055A1/de active Pending
- 1971-12-20 IE IE1611/71A patent/IE35937B1/xx unknown
- 1971-12-20 BR BR8429/71A patent/BR7108429D0/pt unknown
- 1971-12-20 IE IE1610/71A patent/IE35910B1/xx unknown
- 1971-12-20 BR BR8428/71A patent/BR7108428D0/pt unknown
- 1971-12-20 AU AU37100/71A patent/AU465875B2/en not_active Expired
-
1972
- 1972-01-26 LU LU64664D patent/LU64664A1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ambache et al. | The effect of muscarine on perfused superior cervical ganglia of cats | |
| US4022899A (en) | Synergistic local anesthetic compositions | |
| US4029793A (en) | Synergistic local anesthetic compositions | |
| Borzelleca et al. | Studies on the respiratory and cardiovascular effects of (-)-cotinine | |
| NO135892B (enExample) | ||
| Halstead | Fish poisonings‐their diagnosis, pharmacology, and treatment | |
| Bose et al. | Chemical and pharmacological studies on Argemone mexicana | |
| Marinkelle et al. | Toxicological and clinical studies on Centruroides margaritatus (Gervais), a common scorpion in western Colombia. | |
| Hedge | Stimulation of ACTH secretion by indomethacin and reversal by exogenous prostaglandins | |
| Gertner | The effect of compound 48/80 on ganglionic transmission | |
| Vandam | Some aspects of the history of local anesthesia | |
| Ogura et al. | Comparative pharmacological actions of ciguatoxin and tetrodotoxin, a preliminary account | |
| Paton et al. | The ganglion blocking action of procainamide | |
| Shaw et al. | Benzyldimethylbufotenin, a powerful antimetabolite of serotonin | |
| Goetz et al. | Biological neurotoxins | |
| Quilliam | DI-ISO Propyleluorophosphonate (DFP): Its pharmacology and its therapeutic uses in glaucoma and myasthenia gravis | |
| Strover | Snakebite and its treatment | |
| DE1667891B2 (de) | Verwendung von Ribonuclease bei der Schmerzbekämpfung | |
| MASON et al. | A comparison of the rate of absorption from normal and burned tissues | |
| Ivins et al. | Influence of body weight on response of Fischer 344 rats to anthrax lethal toxin | |
| Osman et al. | Neuromuscular blocking activity of snake (Naja melanoleuca, Hallowel) venom | |
| NZ239601A (en) | Use of n-acetyl neuraminic acid for treating kidney diseases | |
| Davis et al. | A Vasopressor Phenomenon Following Intra-arterial Administration of Hypertonic Solutions | |
| Hirayama et al. | A ganglion blocking action of toxic substances is-toxin and surugatoxin, from the Japanese ivory shell, Babylonia Japonica | |
| Plimmer | A critical summary of Ehrlich's recent work on toxins and antitoxins |